Expert reports on big data related topics

The European Medicines Agency (EMA) and the Heads of Medicine Agencies (EMA) publish expert reports on big data to support their regulatory decision-making work. These documents review latest information and trends, and make recommendations for future actions in the field of big data.
HumanVeterinaryCorporateData on medicinesInnovation

The expert reports help guide the work of the HMA-EMA joint Big Data Steering Group

For more information, see:

Mobile health data

A report on mobile health (mHealth) data is available to explore the opportunities of using data from mobile technologies and digital interventions in regulatory decision-making

This report focuses on mHealth data use in real-world settings, such as clinical care or the daily life of patients, to generate real-world evidence

mHealth tools such as smartphones, health applications, smartwatches and other wearables can generate a large variety of detailed patient data like heart rate and body temperature. 

However, they can also pose challenges in terms of data quality and protection of patient privacy.

The HMA-EMA joint Big Data Steering Group published this report in October 2024.

Clusters of excellence on data analytics

A discussion paper is available on how to introduce data analytics into the everyday work of the European medicines regulatory network. 

This paper proposes so-called clusters of excellence operating at national level.

These clusters would support each other's work and share good practice in areas including data access, infrastructure and artificial intelligence. 

Experts from national competent authorities represented on the HMA-EMA joint Big Data Steering Group produced this paper. 

The steering group published it in March 2023.

Social media

A report exploring the potential advantages and challenges of leveraging social media data in regulatory decision-making is available.

The report specifically focuses on the use of social media data in real-world settings, such as clinical care or the daily life of patients, to generate real-world evidence that could potentially support regulatory activities. 

Such data includes:

  • demographic information;
  • patient experience data (PED);
  • data related to medicine use and disease factors.

Although obtaining access to and ensuring appropriate quality and ethical use of social media data can be challenging, it might be is possible to extract valuable patient data from such sources.

In some specific cases, such as medicine abuse / misuse or misinformation, social media data might be used as a complementary source of evidence.

The HMA-EMA joint Big Data Steering Group is continuing to monitor progress in this area, as technological advances might help to overcome some of the current challenges of using such data.

EMA and the steering group are encouraging researchers in this field to conduct further studies, as this could help enhance the EU regulatory system and bring about public health benefits.

The steering group published the report in November 2024.

Share this page